EANS-Adhoc: SYGNIS Pharma AG / Genetrix Life Sciences, A.B., and Genetrix, S.L., Granted Exemption from Mandatory Tender Offer to Shareholders of SYGNIS Pharma AG

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

24.09.2012

Heidelberg, September 24,2012 - SYGNIS Pharma AG (Frankfurt: LIOK;
ISIN DE000A1E9B74; Prime Standard) was informed that the German
Federal Financial Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht; BaFin) has granted an exemption to
Genetrix Life Sciences, A.B., and to its parent company Genetrix,
S.L., from the obligation to publish the acquisition of control over
SYGNIS Pharma AG, and to provide BaFin an offer document, and to
publish a mandatory tender offer, in the event these companies will
gain control over SYGNIS Pharma AG subsequently to the resolution
regarding the capital increase against contribution in kind to be
resolved on the Shareholders' Meeting convened on October 17, 2012,
coming in force.

The resolution regarding the contribution in kind by way of
contributing the shares of X-Pol Biotech, S.L., into SYGNIS Pharma AG
coming in force, Genetrix Life Sciences, A.B., and their parent
company Genetrix, S.L., will acquire control over SYGNIS Pharma AG in
the meaning of Section29 (2) WpÜG and would have been required to
make a mandatory tender offer to the shareholders of SYGNIS Pharma AG
had the exemption not been granted. **** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG

Peter Willinger
Co-CEO/CFO
Tel: +49 6221 454 836
Email: willinger@sygnis.de

### Disclaimer This publication is intended for information only and
constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English